跳至主要内容
临床试验/NCT04542590
NCT04542590已完成不适用

A Natural History Study of Patients With Genetically Confirmed Primary Hyperoxaluria Type 3 and, as Applicable Per Age, a History of Stone Events

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company1 个研究点 分布在 1 个国家目标入组 7 人开始时间: 2021年9月9日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
7
试验地点
1
主要终点
Collect stone formation data in PH3 patients

研究概览

简要总结

This is a natural history study of adults, adolescents, and children (starting at birth) with genetically confirmed primary hyperoxaluria type 3 (PH3) who have a history of stone events during the last 3 years and/or the presence of pre existing stones detected by renal ultrasound at screening.

详细描述

The relationship between the level of Uox and the incidence of kidney stones and/or nephrocalcinosis in patients with PH3 has not been established. The goal of this study is to record 24-hour Uox levels and the incidence of new stone formation and/or the degree of nephrocalcinosis in patients with PH3 over time.

Potential participants are screened over an up-to-7 week period according to the eligibility criteria and will then be followed every 6 months over an up-to-2-year period to determine the annualized new stone formation rate (number of new stones being formed per year) and the change in the degree of nephrocalcinosis (if applicable).

New stone formation is defined as occurrence of any of the following:

  • Spontaneous stone passage in the absence of pre-existing stones
  • Stone passage occurring without change in the number of pre-existing stones detected by renal ultrasound
  • Appearance of new stones on renal ultrasound or 100% or more growth of a pre-existing stone (estimated area)
  • Surgical removal of newly formed stones Note: Spontaneous passage or surgical removal of pre-existing stones does not meet the criteria for new stone formation.

This is a non-interventional study that will last up to 2 years.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
2 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • Prior or planned liver transplant within study period
  • Currently receiving dialysis or anticipating dialysis during study period
  • Unwillingness to comply with study procedures

结局指标

主要结局

Collect stone formation data in PH3 patients

时间窗: Assess participants' stone formation rates over the course of 2 years

Collect data on the rate of new stone formation in PH3 patients of at least 2 years of age

Assess relationship between urine oxalate (Uox) levels and stone formations in PH3 patients

时间窗: Measure participants' Uox levels over the course of 2 years

Explore the potential relationship between Uox levels and new stone formation in patients (≥ 2 years of age) with genetically confirmed PH3 and relatively intact renal function

Collect data on the degree of nephrocalcinosis in PH3 patients

时间窗: Assess the change in nephrocalcinosis grade over the course of 2 years

Collect data on the degree of nephrocalcinosis in PH3 patients of at least 2 years of age

次要结局

未报告次要终点

研究者

发起方
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验